These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 38169476)

  • 1. Hydroxyurea reduces infections in children with sickle cell anemia in Uganda.
    Namazzi R; Bond C; Conroy AL; Datta D; Tagoola A; Goings MJ; Jang JH; Ware RE; Opoka R; John CC
    Blood; 2024 Apr; 143(14):1425-1428. PubMed ID: 38169476
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel use Of Hydroxyurea in an African Region with Malaria (NOHARM): a trial for children with sickle cell anemia.
    Opoka RO; Ndugwa CM; Latham TS; Lane A; Hume HA; Kasirye P; Hodges JS; Ware RE; John CC
    Blood; 2017 Dec; 130(24):2585-2593. PubMed ID: 29051184
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hydroxyurea Dose Escalation for Sickle Cell Anemia in Sub-Saharan Africa.
    John CC; Opoka RO; Latham TS; Hume HA; Nabaggala C; Kasirye P; Ndugwa CM; Lane A; Ware RE
    N Engl J Med; 2020 Jun; 382(26):2524-2533. PubMed ID: 32579813
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hydroxyurea for Children with Sickle Cell Anemia in Sub-Saharan Africa.
    Tshilolo L; Tomlinson G; Williams TN; Santos B; Olupot-Olupot P; Lane A; Aygun B; Stuber SE; Latham TS; McGann PT; Ware RE;
    N Engl J Med; 2019 Jan; 380(2):121-131. PubMed ID: 30501550
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Building capacity to reduce stroke in children with sickle cell anemia in the Dominican Republic: the SACRED trial.
    Sánchez LM; Nieves RM; Latham T; Stuber S; Luden JR; Urcuyo GS; Berges ME; Florencio C; Gonzalez C; Del Villar P; Lane A; Schultz W; Jeste N; Mena R; Ware RE
    Blood Adv; 2018 Nov; 2(Suppl 1):50-53. PubMed ID: 30504201
    [No Abstract]   [Full Text] [Related]  

  • 6. Hydroxyurea for ALL children with sickle cell anemia: What can we learn from Africa?
    Aygun B
    Pediatr Blood Cancer; 2020 Apr; 67(4):e28164. PubMed ID: 31925887
    [No Abstract]   [Full Text] [Related]  

  • 7. Approximately 40 000 children with sickle cell anemia require screening with TCD and treating with hydroxyurea for stroke prevention in three states in northern Nigeria.
    Galadanci AA; Galadanci NA; Jibir BW; Abdullahi SU; Idris N; Gambo S; Ali Abubakar SA; Kabo NA; Bello-Manga H; Haliru L; Bashir I; Aliyu MH; Galadanci JA; DeBaun MR
    Am J Hematol; 2019 Nov; 94(11):E305-E307. PubMed ID: 31423630
    [No Abstract]   [Full Text] [Related]  

  • 8. Expanding the role of hydroxyurea in children with sickle cell disease.
    Rogers ZR; Buchanan GR
    J Pediatr; 2004 Sep; 145(3):287-8. PubMed ID: 15343174
    [No Abstract]   [Full Text] [Related]  

  • 9. Hydroxyurea therapy: improving the lives of patients with sickle cell disease.
    Anderson N
    Pediatr Nurs; 2006; 32(6):541-3. PubMed ID: 17256291
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hydroxyurea prevents onset and progression of albuminuria in children with sickle cell anemia.
    Zahr RS; Hankins JS; Kang G; Li C; Wang WC; Lebensburger J; Estepp JH
    Am J Hematol; 2019 Jan; 94(1):E27-E29. PubMed ID: 30359463
    [No Abstract]   [Full Text] [Related]  

  • 11. Hydroxyurea in Sickle Cell Disease and Invasive Bacterial Infections: A Case-Control Study.
    Pascault A; Koehl B; Brousse V; Benkerrou M; Gaschignard J
    J Pediatric Infect Dis Soc; 2024 Sep; 13(9):493-495. PubMed ID: 38970408
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term use of hydroxyurea for sickle cell anemia.
    Hagar W
    JAMA; 2003 Aug; 290(6):753; author reply 754. PubMed ID: 12915424
    [No Abstract]   [Full Text] [Related]  

  • 13. Increasing hydroxyurea use in children with sickle cell disease at Kamuzu Central Hospital, Malawi.
    Mvalo T; Topazian H; Kamthunzi P; Chen J; Kambalame I; Mafunga P; Mumba N; Chiume-Chiphaliwali M; Paseli K; Key N; Gopal S; Hoffman I; Ataga K; Westmoreland K
    Blood Adv; 2018 Nov; 2(Suppl 1):30-32. PubMed ID: 30504195
    [No Abstract]   [Full Text] [Related]  

  • 14. Interventions for chronic kidney disease in people with sickle cell disease.
    Roy NB; Fortin PM; Bull KR; Doree C; Trivella M; Hopewell S; Estcourt LJ
    Cochrane Database Syst Rev; 2017 Jul; 7(7):CD012380. PubMed ID: 28672087
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Therapy-related acute myelogenous leukemia in a hydroxyurea-treated patient with sickle cell anemia.
    Taylor JG; Darbari DS; Maric I; McIver Z; Arthur DC
    Ann Intern Med; 2011 Nov; 155(10):722-4. PubMed ID: 22084346
    [No Abstract]   [Full Text] [Related]  

  • 16. Hydroxyurea as secondary prevention for stroke in children with sickle cell anemia.
    DeBaun MR
    J Pediatr; 2005 Oct; 147(4):560-1. PubMed ID: 16227052
    [No Abstract]   [Full Text] [Related]  

  • 17. Hydroxyurea for children with sickle cell disease: are we starting too late?
    Mueller BU
    Pediatr Blood Cancer; 2011 Jan; 56(1):3-4. PubMed ID: 21058289
    [No Abstract]   [Full Text] [Related]  

  • 18. Blood transfusion for preventing primary and secondary stroke in people with sickle cell disease.
    Estcourt LJ; Fortin PM; Hopewell S; Trivella M; Wang WC
    Cochrane Database Syst Rev; 2017 Jan; 1(1):CD003146. PubMed ID: 28094851
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Blood transfusion for preventing primary and secondary stroke in people with sickle cell disease.
    Estcourt LJ; Kohli R; Hopewell S; Trivella M; Wang WC
    Cochrane Database Syst Rev; 2020 Jul; 7(7):CD003146. PubMed ID: 32716555
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hydroxyurea use among children with sickle cell anemia.
    Reeves SL; Jary HK; Gondhi JP; Raphael JL; Lisabeth LD; Dombkowski KJ
    Pediatr Blood Cancer; 2019 Jun; 66(6):e27721. PubMed ID: 30900800
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.